Trilogy Capital’s Teladoc Health TDOC Stock Holding History

Trilogy Capital’s Portfolio TDOC Stock Details TDOC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-77	Closed	-$7K	–	513
2018 Q3	$7K	Buy	+77	New	+$5.49K	﹤0.01%	362

Other funds holding TDOC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ZCI

Zevenbergen Capital Investments Edmonds, Washington $4.37B AUM 52.9% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Trilogy Capital's TDOC Position: Q4 2018 in Review

Trilogy Capital sold out of Teladoc Health (TDOC) in Q4 2018, closing a stake of 77 shares — an estimated $7K sold.

Trilogy Capital first reported a position in TDOC in Q3 2018 and held it in 1 quarter. The position peaked at $7K in Q3 2018. 326 funds tracked by Wall St. Rank hold TDOC as of Q4 2018.

Trilogy Capital reported no remaining Teladoc Health position as of Q4 2018 after selling out during the quarter.
Trilogy Capital sold 77 Teladoc Health shares in Q4 2018, an estimated $7K.
Trilogy Capital first reported a position in Teladoc Health in Q3 2018 and held it in 1 quarter.
Trilogy Capital's Teladoc Health position peaked at $7K in Q3 2018.
326 funds tracked by Wall St. Rank held Teladoc Health as of Q4 2018.

Based on Trilogy Capital's 13F filing for Q4 2018, filed 15 Jan 2019.